Olympus Corporation announced consolidated and non consolidated earnings results for the year ended March 31, 2013. For the year, on consolidated basis, the company reported net income of JPY 8,020 million or JPY 28.96 net income per share on net sales of JPY 743,851 million compared to net loss of JPY 48,985 million or JPY 183.54 net loss per share on net sales of JPY 848,548 million for the prior year. Operating and ordinary income were JPY 35,077 million and JPY 13,046 million against JPY 35,518 million and JPY 17,865 million of prior year. Return on equity was 8.3% against negative 62.3% of prior year. Cash flow from operating activities was JPY 25,233 million against JPY 30,889 million of prior year. Income before provision for income taxes was JPY 19,142 million against loss before provision for income taxes of JPY 9,495 million of prior year. Purchase of property, plant and equipment was JPY 24,023 million against JPY 22,761 million of prior year. Purchases of intangible assets were JPY 3,942 million against JPY 12,483 million of prior year. The company provided earnings guidance for the six months of 2014 and full year ending March 31, 2014. For the six months, the company forecasts net income of JPY 10,000 million or JPY 33.20 net income per share on net sales of JPY 335,000 million. The company forecasts operating and ordinary income of JPY 27,000 million and JPY 17,500 million. For the full year 2014, the company forecasts net income of JPY 30,000 million or JPY 99.59 net income per share on net sales of JPY 700,000 million. The company forecasts operating and ordinary income of JPY 71,000 million and JPY 48,000 million. For the year, on non consolidated basis, the company reported net income of JPY 16,789 million or JPY 60.62 net income per share on net sales of JPY 71,400 million compared to net loss of JPY 32,933 million or JPY 123.39 net loss per share on net sales of JPY 74,033 million. Operating loss and ordinary income were JPY 5,870 million and JPY 8,529 million against operating and ordinary loss of JPY 11,755 million and JPY 13,876 million of prior year.

Olympus announced that the company's ultrasound endoscopes will now be powered by the ProSound F75 Ultrasound Processor. The ProSound F75 Ultrasound Processor, developed in partnership by Hitachi Aloka Medical Ltd., provides physicians with the high quality imaging--that aids in more accurate diagnosis of diseases of the GI track and surrounding organs such as the pancreas, bile duct, liver, spleen and gallbladder as well as assessing a variety of cancers. The newly introduced platform improves workflow from pre-examination to after examination for better data management, and provides improved visualization for more accurate blood flow information. The ProSound F75 Ultrasound Processor offers a unique ergonomic capability with an adjustable height and depth of the keyboard and monitor that provides comfort to all endoscopists in a practice. The ProSound F75 has versatile capabilities for conducting quick tasks and examinations in every clinical setting. In addition, the device is forward and backward compatible which allows it to work with most endoscopic ultrasound (EUS) and endobronchial ultrasound (EBUS) scopes. This technology addresses the key requirements of healthcare reform: increased quality of care, decreased costs and enhanced patient satisfaction.

Olympus Corporation announced that they will report fiscal year 2013 results on May 15, 2013